DBP and the bioavailability and function of vitamin D

描述（由申请人提供）：在过去的十年里，维生素D研究有了显着的复兴。两个关键概念支撑了对维生素D健康益处的重新关注。首先是关于维生素D不足的全球流行率的持续辩论，以及如何通过传统的阳光照射和饮食摄入安全地获得最佳的维生素D状态。其次是维生素D促进健康益处的潜力，超越了其对骨骼的经典作用。在最近的数据审查之后，医学研究所（IOM）发表了旨在解决有关我们对维生素D和人类健康的新观点的一些关键问题的声明。根据骨骼对维生素D的反应，所有年龄组的维生素D推荐膳食摄入量都有所提高。然而，IOM的报告也认识到需要进一步研究，以更好地定义维生素D的“非经典”健康益处。这些建议的长期影响主要取决于一个问题-如何定义维生素D充足和不足？拟议的项目描述了一种新的模式，用于量化最佳维生素D及其与人类健康的关系。总体目标是证明维生素D活性不是简单地由25-羟基维生素D（25 D）的总血清水平定义的，而是取决于这种代谢物对靶细胞的生物利用度及其随后通过酶1 β-羟化酶（CYP 27 B1）转化为活性1，25-二羟基维生素D（1，25 D）。该提案假设25 D进入靶细胞的能力受到其与血清维生素D结合蛋白（DBP）的结合的影响，“游离”而不是“DBP结合”25 D是该代谢物的生物活性形式。该提案的总体目标是使用小鼠和人体模型研究DBP对25 D生物活性的影响。使用转基因、基因敲除和人源化小鼠的研究将调查DBP的浓度和维生素D代谢物结合亲和力的变化如何影响这些小鼠在维生素D充足和缺乏的条件下对25 D和1，25 D的反应。这些实验的数据将与人体研究相关，其中DBP浓度和结合亲和力受到DBP基因遗传变异的强烈影响。人体研究将在具有多种维生素D功能测量的大型患者队列中纳入DBP和游离25 D/1，25 D的分析，但也将涉及利用亲本维生素D或25 D的试点补充研究。这些分析将采用新的数学算法来测定血清游离25 D和1，25 D，并将使用新的测定技术来物理测量血清游离25 D水平。该模型不仅提出了一种定义最佳维生素D状态的新范式，而且还旨在突出对维生素D健康的更具“个性化”的观点，该观点将结合维生素D的经典和非经典作用。 .

DESCRIPTION (provided by applicant): In the last ten years there has been a remarkable renaissance in vitamin D research. Two key concepts have underpinned this renewed interest in the health benefits of vitamin D. First is the continuing debate on the worldwide prevalence of vitamin D-insufficiency, and how optimal vitamin D status can be safely achieved through conventional exposure to sunlight and dietary intake. Second is the potential for vitamin D to promote health benefits beyond its classical effects on the skeleton. Following a recent data review, the Institute of Medicine (IOM) has issued statements aimed at addressing some of the key questions concerning our new perspective on vitamin D and human health. The Recommended Dietary Allowance of vitamin D for all age groups was elevated based on bone responses to vitamin D. However, the IOM report also recognized the need for further research to better define 'non-classical' health benefits of vitamin D. The long-term impact of these recommendations is crucially dependent on one question - how does one define vitamin D-sufficiency and -insufficiency? The proposed project describes a new paradigm for quantifying optimal vitamin D and its relation to human health. The overall aim is to demonstrate that vitamin D activity is not simply defined by total serum levels of 25-hydroxyvitamin D (25D) but instead depends on the bioavailability of this metabolite to target cells and its subsequent conversion to active 1,25-dihydroxyvitamin D (1,25D) via the enzyme 1�-hydroxylase (CYP27B1). The proposal hypothesizes that the ability of 25D to access target cells is influenced by its association with the serum vitamin D binding protein (DBP), with 'free' rather than 'DBP-bound' 25D being the bioactive form of this metabolite. The overall objective of the proposal will be to investigate the impact of DBP on the bioactivity of 25D using both mouse and human models. Studies using transgenic, knockout, and humanized mice will investigate how variations in the concentration and vitamin D metabolite binding affinity of DBP affect the response of these mice to 25D and 1,25D under conditions of vitamin D-sufficiency and -deficiency. Data from these experiments will then be related to studies in humans, where DBP concentration and binding affinity are strongly influenced by genetic variations in the DBP gene. Human studies will incorporate analysis of DBP and free 25D/1,25D in a large patient cohort with multiple measures of vitamin D function, but will also involve a pilot supplementation study utilizing parental vitamin D or 25D. These analyses will employ a new mathematical algorithm for determining serum free 25D and 1,25D and will use novel assay technology to physically measure serum levels of free 25D. This model not only puts forward a new paradigm for defining optimal vitamin D status but also aims to highlight a more 'personalized' perspective on vitamin D health that will incorporate both classical and non-classical actions of vitamin D. .